Phenotype Genotype and Biomarkers 2 (PGB2)

Brief description of study

The purpose of this study is to learn more about amyotrophic lateral sclerosis (ALS) and other related neurodegenerative diseases, including frontotemporal dementia (FTD), primary lateral sclerosis (PLS), hereditary spastic paraplegia (HSP), progressive muscular atrophy (PMA) and multisystem proteinopathy (MSP). More precisely, we want to identify the links that exist between the disease phenotype (phenotype refers to observable signs and symptoms) and the disease genotype (genotype refers to your genetic information). We also want to identify biomarkers of ALS and related diseases. A biomarker is an indicator of the disease that can easily be measured. Our long-term goal is to use this information to advance the development of therapies for this group of neurodegenerative disorders.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Medical Research, ALS
Age: Between 7 Years - 99 Years
Gender: All

1) have or are suspected to have ALS or a related disease (primary participant) 2) have a family member affected with ALS or a related disease who is already taking part in the study (secondary participant).

Updated on 09 Mar 2024. Study ID: 848675

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).